Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome

Leukemia volume 18, pages 361–362 (2004)Cite this article

TO THE EDITOR

Clonal evolution in Philadelphia chromosome negative (Ph−) cells of chronic myeloid leukaemia (CML) patients successfully treated with imatinib mesylate has been recently reported with increasing frequency.1,2,3,4,5,6 The most common change is trisomy 8, but −7 as well as other karyotype aberrations have also been observed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, Dufva IH, Brondum-Nielsen K . Clonal Ph− negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia 2002; 16: 1390–1395.

    Article  CAS  Google Scholar 

  2. Braziel RM, Launder TM, Druker BJ, Olson SB, Magenis RE, Mauro MJ et al. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood 2002; 100: 435–441.

    Article  CAS  Google Scholar 

  3. Chee YL, Vickers MA, Stevenson D, Holyoake TL, Culligan DJ . Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones. Leukemia 2003; 17: 634–635.

    Article  CAS  Google Scholar 

  4. Marktel S, Marin D, Foot N, Szydlo R, Bua M, Karadimitris A et al. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica 2003; 88: 260–267.

    CAS  PubMed  Google Scholar 

  5. Meeus P, Demuynck H, Martiat P, Michaux L, Wouters E, Hagemeijer A . Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with imatinib. Leukemia 2003; 17: 465–467.

    Article  CAS  Google Scholar 

  6. Royer-Pokora B, Hildebrandt B, Redmann A, Herold C, Kronenwett R, Haas R et al. Simultaneous occurrence of a t(9;22) (Ph) with a t(2;11) in a patient with CML and emergence of a new clone with the t(2;11) alone after imatinib mesylate treatment. Leukemia 2003; 17: 807–810.

    Article  CAS  Google Scholar 

  7. De Felice L, Di Pucchio T, Mascolo MG, Agostini F, Breccia M, Guglielmi C et al. Flt3L induces the ex-vivo amplification of umbilical cord blood committed progenitors and early stem cells in short-term cultures. Br J Haematol 1999; 106: 133–144.

    Article  CAS  Google Scholar 

  8. Goldberg SL, Madan RA, Rowley SD, Pecora AL, Hsu JW, Tantravahi R . Myelodysplastic subclones in chronic myeloid leukemia: implications for imatinib mesylate therapy. Blood 2003; 101: 781.

    Article  CAS  Google Scholar 

  9. Bumm T, Muller C, Al-Ali HK, Krohn K, Shepherd P, Schmidt E et al. Emergence of clonal cytogenetic abnormalities in Ph− cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003; 101: 1941–1949.

    Article  CAS  Google Scholar 

  10. Burchert A, Wolfl S, Schmidt M, Brendel C, Denecke B, Cai D et al. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 2003; 101: 259–264.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cellular Biotechnologies and Hematology, University ‘La Sapienza’ of Rome, Roma, Italy

    G Alimena, M Breccia, M Mancini, G Ferranti, L De Felice, C Gallucci & F Mandelli

Authors
  1. G Alimena
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Breccia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Mancini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Ferranti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L De Felice
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Gallucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F Mandelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alimena, G., Breccia, M., Mancini, M. et al. Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome. Leukemia 18, 361–362 (2004). https://doi.org/10.1038/sj.leu.2403210

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403210

This article is cited by

Search

Advanced search

Quick links